Comparative Pharmacology
Head-to-head clinical analysis: ALOCRIL versus GASTROCROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOCRIL versus GASTROCROM.
ALOCRIL vs GASTROCROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from conjunctival mast cells. Also inhibits eosinophil chemotaxis and activation.
Mast cell stabilizer; inhibits degranulation of mast cells and release of histamine and other inflammatory mediators.
2 drops in each eye four times daily; ophthalmic route.
200 mg orally four times daily, 30 minutes before meals and at bedtime.
None Documented
None Documented
8.6 hours (terminal elimination half-life in healthy adults; may be prolonged in renal impairment, e.g., up to 18 hours in patients with severe renal dysfunction).
Terminal elimination half-life is approximately 1–1.5 hours following intravenous administration. The apparent half-life after oral inhalation is longer due to slow absorption from the lungs, but systemic half-life remains short, requiring frequent dosing for sustained effect.
Renal (primarily unchanged drug; approximately 50-60% excreted unchanged in urine within 48 hours). Biliary/fecal elimination accounts for <10%.
Primarily excreted unchanged in bile and feces via enterohepatic circulation; renal excretion accounts for approximately 1-2% of an oral dose. After intravenous administration, about 50% is excreted unchanged in urine within 48 hours.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer